The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).
The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018 Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
http://cdmrp.army.mil/pubs/press/2018/18kcrppreann
Concept Award
Investigators at all academic levels.
· Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.
· Emphasis on innovation.
· Funding for clinical trials is not allowed.
· Preliminary data are not allowed.
· Blinded review
· Maximum funding of $75,000 for direct costs (plus indirect costs).
· Maximum period of performance is 1 year.
Idea Development Award
Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
· Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
· Preliminary data are required.
· Innovation and Impact are the most important review criteria.
· Funding for clinical trials is not allowed.
· FY18 KCRP Areas of Emphasis are strongly encouraged.
· Maximum funding of $400,000 in direct costs (plus indirect costs).
· Period of performance is not to exceed 2 years.
Physicians Research Award
The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent
· Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.
· This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.
· Emphasis on multi-institutional/multi-disciplinary and collaboration.
· Preliminary data are not required.
· Funding for clinical trials is not allowed
· Maximum funding of $200,000 in direct costs (plus indirect costs).
· Period of performance is not to exceed 2 years.
Technology Development Award
Independent investigators at or above the level of Assistant Professor (or equivalent).
· Supports emerging technologies to aid clinical and patient outcomes.
· Preliminary data are required (need not be in kidney cancer).
· Funding for clinical trials is not allowed.
· Maximum funding of $300,000 in direct costs (plus indirect costs).
· Period of performance is not to exceed 3 years.
Translational Research Partnership
Investigators at or above the level of Assistant Professor (or equivalent).
· Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
· Supports translational correlative studies.
· Preliminary data are required.
· Funding for clinical trials is not allowed.
· Maximum funding of $600,000 for direct costs (plus indirect costs).
· Maximum period of performance is 3 years.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
Promoting Partnerships To Improve Veterans’ Health